EASi-HF - A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) >40%

drug protocol number

1378-0020

drug sponsor

Boehringer Ingelheim

drug study

BI 690517 , empagliflozin

drug trial site

1-King Fahad Medical City (Riyadh) 2-King Khalid University Hospital (Riyadh) 3-King Faisal Specialist Hospital and Research Center (Riyadh) 4-King Abdulaziz Medical City NG (Riyadh) 5-King Abdulaziz University Hospital (Jeddah)

drug status

Ongoing

drug phase